Page 2 - Nasdaq Stro News Today

Sutro Biopharma (NASDAQ:STRO – Free Report) had its target price lowered by Wedbush from $20.00 to $12.00 in a report released on Friday, Marketbeat reports. The firm currently has an outperform rating on the stock. Sutro Biopharma Stock Performance NASDAQ:STRO opened at $4.29 on Friday. The stock’s 50 day moving average price is $4.78 and […]

HC Wainwright reissued their buy rating on shares of Sutro Biopharma (NASDAQ:STRO – Free Report) in a research note published on Friday, Benzinga reports. They currently have a $16.00 target price on the stock. Separately, Wedbush decreased their price target on shares of Sutro Biopharma from $20.00 to $12.00 and set an outperform rating on […]

Sutro Biopharma (NASDAQ:STRO – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09, reports. Sutro Biopharma had a negative return on equity of 65.07% and a negative net margin of 250.87%. The company had revenue […]

Sutro Biopharma (NASDAQ:STRO – Get Free Report) issued its earnings results on Thursday. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09, reports. The firm had revenue of $10.41 million during the quarter, compared to analyst estimates of $10.45 million. Sutro Biopharma had a negative net […]

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,940,000 shares, a decline of 36.8% from the June 15th total of 3,070,000 shares. Based on an average daily volume of 512,700 shares, […]

Sutro Biopharma (NASDAQ:STRO – Free Report) and Codiak BioSciences (NASDAQ:CDAK – Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Profitability This table compares Sutro Biopharma and Codiak BioSciences’ […]

- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab...

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) have received a consensus rating of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year […]

Sutro Biopharma (NASDAQ:STRO – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends. Institutional and Insider Ownership 87.6% of Sutro Biopharma shares […]

Sutro Biopharma (NASDAQ:STRO – Get Rating) and Cardiol Therapeutics (NASDAQ:CRDL – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Valuation & Earnings This table compares Sutro Biopharma and […]